Xiaoyu Ai

Dr. Xiaoyu Ai


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 April 2025 in AAPS PharmSciTech
Verified
Journal Article
Closed access
PDF file
HLHongting Liu
Hongting Liu
YSYao Sun
Yao Sun
SCShihao Cai
Shihao Cai
CZConglu Zhao
Conglu Zhao
XXXiang Xu
Xiang Xu
XAXiaoyu Ai
Xiaoyu Ai

16 November 2023 in AAPS PharmSciTech
Verified
Journal Article
Closed access
PDF file
ZLZhilin Luo
Zhilin Luo
LJLiyuan Ji
Liyuan Ji
HLHongting Liu
Hongting Liu
YSYao Sun
Yao Sun
CZConglu Zhao
Conglu Zhao
CYCheng Yang
Cheng Yang

20 December 2021 in AAPS PharmSciTech
Verified
Journal Article
Closed access
PDF file
ZWZhenzhen Wang
Zhenzhen Wang
LJLiyuan Ji
Liyuan Ji
YRYimeng Ren
Yimeng Ren
MLMenghan Liu
Menghan Liu
XAXiaoyu Ai
Xiaoyu Ai
CYCheng Yang
Cheng Yang

21 May 2025 in Frontiers in Microbiology
Verified
Journal Article
Open access
PDF file
XGXiaoting Gu
Xiaoting Gu
SZShuwen Zhu
Shuwen Zhu
WTWeixue Tian
Weixue Tian
XLXiaohe Li
Xiaohe Li
YCYutian Cai
Yutian Cai
CYCheng Yang
Cheng Yang
Introduction: Chemotherapy induced constipation (CIC) is a gastrointestinal side effect that occurs in patients receiving chemotherapy, which can further deteriorate the living quality of cancer patients. Deglycosylated azithromycin (Deg-AZM), a newly developed Class I drug with good therapeutic effects on chronic constipation, has been approved for clinical trials in 2024. However, it is unclear whether Deg-AZM has any impact on gut microbiota of CIC mice. The purpose of this study was to explore the role of Deg-AZM in treating CIC by modulating the gut microbiota.Methods: The therapeutic effects of Deg-AZM on intestinal motility were assessed in a cisplatin-induced CIC mouse model. The gut microbiota composition was analyzed using 16S rRNA sequencing, and metabolic changes were evaluated through untargeted metabolomics of fecal samples.Results: Deg-AZM significantly enhanced intestinal motility in the mice with cisplatin-evoked constipation. Gut microbiota analysis revealed that Deg-AZM altered the community composition by decreasing Deferribacterota and Pseudomonadota and increasing Bacteroidota, Lactobacillus and Muribaculaceae. The feces metabolomics revealed that alanine, aspartate and glutamate metabolism, citrate cycle (TCA cycle), purine metabolism, primary bile acid biosynthesis and taurine and hypotaurine metabolism in CIC model were modulated by Deg-AZM.Conclusion: Deg-AZM could alleviate cisplatin-evoked constipation in mice by reshaping the structure of gut microbial community, which may provide a potential basis for the use and clinical development of Deg-AZM for CIC treatment.

10 October 2024 in International Immunopharmacology
Verified
Journal Article
Closed access
ZLZhichao Liu
Zhichao Liu
ZLZhigang Liu
Zhigang Liu
WLWenqi Li
Wenqi Li
ZYZhongyi Yang
Zhongyi Yang
LMLingxin Meng
Lingxin Meng
HZHonggang Zhou
Honggang Zhou

31 May 2025 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
YSYao Sun
Yao Sun
SCShihao Cai
Shihao Cai
HLHongting Liu
Hongting Liu
CZConglu Zhao
Conglu Zhao
XXXiang Xu
Xiang Xu
CYCheng Yang
Cheng Yang